Association of accelerated switch from vertebral end‐plate Modic I to Modic 0 signal changes with clinical benefit of intradiscal corticosteroid injection for chronic low back pain
Modic I vertebral end‐plate signal changes detected by magnetic resonance imaging (MRI) are associated with chronic low back pain. Typically, Modic I signal changes in untreated patients switch to non–Modic I signal changes within 3 years, which reflect spontaneous healing. Recent findings suggest t...
Saved in:
Published in | Arthritis & rheumatology (Hoboken, N.J.) Vol. 63; no. 9; pp. 2828 - 2831 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.09.2011
Wiley Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Modic I vertebral end‐plate signal changes detected by magnetic resonance imaging (MRI) are associated with chronic low back pain. Typically, Modic I signal changes in untreated patients switch to non–Modic I signal changes within 3 years, which reflect spontaneous healing. Recent findings suggest that Modic I signal changes may be related to local inflammatory changes, providing a rationale for treatment with intradiscal injections of antiinflammatory drugs. In the present report, we describe a 31‐year‐old man with 1‐year history of chronic low back pain associated with vertebral end‐plate Modic I signal changes, who received 1 intradiscal corticosteroid injection in L5–S1. Local treatment led to rapid pain relief and was associated with an accelerated switch from Modic I to Modic 0 signal changes, as seen on lumbar MRI at 1‐month followup. This is the first report of an effective local treatment for both the symptoms and the structural changes of chronic low back pain that are associated with Modic I signal changes. Additionally, this case reinforces the hypothesis that local inflammation has a pathogenic role. |
---|---|
Bibliography: | Dr. Rannou has received consulting fees, speaking fees, and/or honoraria from Merck, Sharp, and Dohme, Expanscience, Genévrier, Rottapharm, and GlaxoSmithKline (less than $10,000 each). Dr. Poiraudeau has received consulting fees, speaking fees, and/or honoraria from Sanofi Aventis, Pfizer, and Merck, Sharp, and Dohme (less than $10,000 each). ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
ISSN: | 0004-3591 2326-5191 1529-0131 2326-5205 |
DOI: | 10.1002/art.30443 |